leisure time -WSS

leisure time

author：knowledge 2025-09-06 03:53:08 - browse：52

Illumina said Monday afternoon that its board of directors had approved a spin-off of its cancer test subsidiary Grail, signaling that a nearly four-year-long, $8 billion saga will finally draw to a close this month.

Shares in the newly independent Grail are expected to be distributed on June 24, Illumina said in a statement. Illumina will retain a 14.5% stake in the company, which will trade under the ticker $GRAL.

It’s the second time Illumina has spun off Grail, which initially began as a unit within the DNA sequencing giant in 2015. Illumina turned it into an independent company the following year but then agreed to reacquire it for $8 billion in September 2020.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies
Next article： GOP presidential candidates start declaring their loyalty

hotspot

WSS

House GOP releases memo on Hunter Biden foreign business dealings, reviving old claims

Newly revealed memo details efforts to keep Trump in power following election loss

Timeline: Special counsel's investigation into Trump's handling of classified documents

GOP presidential candidates start declaring their loyalty

Trump, Nauta plead not guilty to new classified docs charges but De Oliveira still not arraigned

EpiPen alternative approval delay highlights citizen petition issue

explore

leisure time

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

knowledge

Moonlake's readout produced a cash windfall. Risks remain

Case for ALS therapy Nurown relies on ‘deficient’ data, FDA finds

The high cost of giving birth even with insurance

Readout LOUD podcast: possible new ALS drug, artificial wombs

Bright Health sells Medicare Advantage business to Molina

Changes to biosimilar regulatory framework must prioritize patients

Duchenne breakthrough therapy leaves behind pioneering families

Covid's long

Dobbs anniversary: the lost opportunity of abortion as health care

NYC stabbing: Teen named, arraigned by District Attorney in O'Shae Sibley death

focus

Second xenotransplant done with gene

Hearing on Medicare drug price negotiation gets unusually heated

Genentech weighs delaying cancer therapy after drug pricing law

After John Oliver segment, STAT readers share their opioid

Thermo Fisher plant for manufacturing gene therapies to expand

Newly revealed memo details efforts to keep Trump in power following election loss

hotspot

hotspot

hotspot

hotspot